Welcome to our dedicated page for BriaCell Therapeutics Warrant news (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics Warrant stock.
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company based in Los Angeles. They specialize in developing targeted and safe immunotherapy approaches for cancer management, with a current focus on breast cancer. The company has seen success with their patented 'BriaVax' vaccine in FDA Phase I studies, showing promising results. BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology. They are also working on Bria-OTS, personalized immunotherapy for advanced-stage breast cancer.
Rhea-AI Summary
BriaCell to host virtual KOL event on Bria-IMT™ potential in advanced metastatic breast cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.07%
Tags
-
Rhea-AI Summary
BriaCell partners with NYCBS to evaluate Bria-IMT combination in Phase 3 study for advanced breast cancer patients in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.52%
Tags
-
Rhea-AI Summary
BriaCell's pivotal Phase 3 study of Bria-IMT™ in combination with an immune checkpoint inhibitor has been fully approved and will enroll patients with advanced metastatic breast cancer. Positive results could lead to full approval and marketing authorization for Bria-IMT™. The study's primary endpoint is overall survival. Bria-IMT™ is currently under Fast Track Designation by the FDA. Successful completion of the study would allow BriaCell to submit a Biologics License Application.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.17%
Tags
Rhea-AI Summary
BriaCell reports strong patient survival benefit in advanced metastatic breast cancer patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.14%
Tags
-
Rhea-AI Summary
BriaCell closes arrangement, spinning out pipeline assets to BriaPro Therapeutics Corp. BriaCell shareholders receive one common share of SpinCo for each BriaCell share held, and new common shares of BriaCell. BriaCell retains 66.6% of SpinCo common shares. BriaCell common shares to begin trading on September 5, 2023. Refer to proxy statement for more details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
-
Rhea-AI Summary
BriaCell announces plans for Phase 2 clinical study of Bria-IMT™ in combination with a check point inhibitor in TNBC patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
Rhea-AI Summary
BriaCell receives court approval for plan of arrangement to spin-out pipeline assets to BriaPro Therapeutics Corp.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
Rhea-AI Summary
Shareholders approved spinout of BriaPro Therapeutics including pipeline assets for cancer treatment. Share reorganization expected by August 31, 2023. Closing subject to court and regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
-
News
Rhea-AI Summary
BriaCell Therapeutics Corp. has been awarded a research grant by the National Cancer Institute (NCI) to advance its platform of personalized off-the-shelf immunotherapies for cancer. The non-dilutive grant will be used for the development of Bria-OTS™ for advanced metastatic breast cancer, prostate cancer, lung cancer, and melanoma. The company's approach has shown promising top-line survival and quality of life outcomes in patients. The NCI award validates their approach and may lead to future non-dilutive funding opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
News
Rhea-AI Summary
IPA (IMMUNOPRECISE ANTIBODIES LTD.) reported a 6.7% increase in revenue for the fiscal year 2023, reaching $20.7 million. Adjusted for currency effects, the growth was 9.0%. The company also achieved its highest quarterly revenue total of $5.6 million. IPA's CEO, Dr. Jennifer Bath, expressed optimism for the future, highlighting the potential of their in silico suite of services and data management capabilities to drive growth in the coming year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
FAQ
What is the current stock price of BriaCell Therapeutics Warrant (BCTXW)?
The current stock price of BriaCell Therapeutics Warrant (BCTXW) is $0.335 as of November 22, 2024.
What is BriaCell Therapeutics Corp focused on?
BriaCell is focused on immuno-oncology with the development of safe and targeted approaches for cancer management.
What is the significance of BriaVax vaccine?
BriaVax, a patented vaccine by BriaCell, has shown unprecedented results in FDA Phase I studies for late-stage breast cancer patients.
What upcoming clinical trial is BriaCell preparing for?
BriaCell is gearing up for a Phase I/II study to broaden the application of their vaccine technology to a larger number of breast cancer patients.
What is Bria-OTS and its purpose?
Bria-OTS is an off-the-shelf personalized immunotherapy being developed by BriaCell for the treatment of advanced-stage breast cancer patients by matching their HLA type.
Where is BriaCell Therapeutics Corp headquartered?
BriaCell is headquartered in Los Angeles, California.
How can I contact BriaCell for more information?
You can contact BriaCell through their President & CEO, William V. Williams, at 1-888-485-6340 or email info@briacell.com.
Who is the Media Relations contact for BriaCell?
Jules Abraham from CORE IR serves as the Media Relations contact for BriaCell and can be reached at julesa@coreir.com.
How can investors get in touch with BriaCell?
For investor relations, you can contact CORE IR at investors@briacell.com.
What type of clinical trial is BriaCell conducting for breast cancer?
BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT for metastatic breast cancer patients.
What is BriaCell's outlook on expanding their technology?
While currently focused on breast cancer, BriaCell aims to potentially apply its vaccine technology to other cancer types as well in the future.
BriaCell Therapeutics Corp. Warrant